My Courses

n October 30, President Biden issued the long-awaited Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (AI), the first order to navigate AI’s impact across sectors and to help agencies and consumers harness the benefits of AI while mitigating risks….By: Pillsbury Winthrop Shaw Pittman LLP

On October 30, 2023, President Biden published a landmark Executive Order regarding the use of Artificial Intelligence (“AI”) with an accompanying Fact Sheet, touching on the opportunities these systems present along with their potential risks. This Executive Order builds on prior AI-related publications by President Biden, including the Blueprint for an AI Bill of Rights…

On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines. The first phase will include a policy roundtable with stakeholders on December 5 (English) and December 6 (French), at which stakeholders will be invited to share their views on certain themes,…

On October 30, 2023, President Joe Biden signed his Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (AI EO), which addresses artificial intelligence issues, including safety, security, privacy, civil rights, immigration, and health care.  The White House also released a companion Fact Sheet summarizing the AI EO (the “Fact…

D.R. by Rodriguez v. Santos Bakery, Inc., No. 20-CV-3628 (KHP), 2023 WL 3736441 (S.D.N.Y. May 31, 2023) – This decision relates to several motions in limine and the Southern District Court’s determination as to what evidence was not admissible at trial….By: Marshall Dennehey

Depression during pregnancy, or prepartum depression, is a common condition that an estimated ten percent of women in the United States experience. The development of selective serotonin reuptake inhibitors (“SSRI”) offered pregnant women hope in the form of a pill they can take to reduce or eliminate their depression symptoms. However, various medical studies dating…

Juries in Philadelphia and San Diego recently awarded damages of $175 million and $332 million to two men who were diagnosed with non-Hodgkin lymphoma after being exposed to the weedkiller Roundup. The two verdicts are Bayer and Monsanto’s second and third legal defeats over the last month in Roundup litigation. Bayer has set aside roughly…

The U.S. Food and Drug Administration’s (FDA’s) broad definition of “misbranding” has created some industry confusion, while the Federal Trade Commission’s (FTC’s) updates to its Health Products Compliance Guidance have done the same. In light of these recent actions, what challenges are dietary supplement manufacturers now facing? On this episode, Epstein Becker Green attorneys Jack…